Patent applications published 18 May 2011

Published: 6-Jul-2011
Patient Experience

Selected patent applications from the weekly European Patents Bulletin


  • Salts, aqueous liquid compsns containing salts of (S)-(+)-abscisic acid and methods of preparation
    Valent Biosciences 2320727*

  • Taxane compounds for treating eye disease
    Osiris Therapeutics 2320728*

  • Glycoside compounds and pharmaceutical compsns thereof
    Centrose 2320729*

  • Methods and compsns for sleep disorders and other disorders
    Intra-Cellular Therapies 2320731*

  • Substituted imidazole combination
    Pfizer 2320732*

  • Flavin derivatives
    BioRelix 2320734*

  • Pyrazolo-[1,5-A]-pyridine as mark inhibitors
    Merck & Co 2320737*

  • Substituted aminothiazole derivatives, pharmaceutical compsns and methods of use
    TransTech Pharma 2320738*

  • Pharmaceutical compsns and methods for stabilising the same
    The Medicines Company 2320739*

  • Pharmaceutical compsns and methods for producing low impurity concentrations of the same
    The Medicines Company 2320740*

  • Process for making microparticles
    Critical Pharmaceuticals 2320872*

  • Telmisartan tablets
    Zentiva 2320873*

  • Solid pharmaceutical compsn comprising exemestane
    Arrow International 2320874*

  • Secure tracking of tablets
    I-Property Holding 2320875*

  • Hydroxypropyl cellulose capsule shell
    Pfizer 2320876*

  • Treatment of acute myocardial infarction (AMI) using encapsulated cells encoding and secreting GLP-1 peptides or analogues thereof
    Biocompatibles UK 2320877*

  • Monoterpenes for treating respiratory tract diseases, in particular bronchopulmonary diseases
    Maria Clementine Martin Klosterfrau Vertriebsgesellschaft 2320878*

  • Pharmaceutical compsn comprising jasmonates
    Fehr Pereira Lopes 2320879*

  • Naphthaquinone derivatives useful for prevention of amyloid deposits and treatment of diseases involving amyloidogenesis
    Ramot at Tel-Aviv University 2320880*

  • Cannabinoids in combination with non-cannabinoid chemotherapeutic agents (eg serm or alkylating agents)
    GW Pharma 2320881*

  • A synthetic vaccine component
    The University of Melbourne 2320882*

  • Compsns and methods for influencing satiety, lipid metabolism and fat utilisation
    Nestec 2320883*

  • Phosphate binding materials and their uses
    Medical Research Council Technology 2320884*

  • Patches and methods for the transdermal delivery of a therapeutically effective amount of iron
    Fe3 Medical 2320885*

  • Glucosylceramide synthase inhibition for the treatment of collapsing glomerulotherapy and other glomerular disease
    Genzyme 2320886*

  • Pharmaceutical compsns comprising lignans and their derivatives for treating hyperplastic diseases
    Universität Innsbruck; Stuppner, Hermann; Schwaiger, Stefan; Bernhard, David; Laufer, Günther 2320887*

  • Laidlomycin compsns and methods
    Alpharma 2320888*

  • Methods for enhancing energy metabolism
    Nestec 2320889*

  • Indication of use of erdosteine as antidote in a large number of intoxications, especially in heavy metals like lead or mercury, and paracetamol
    Rafifarm 2320890*

  • Butyrylcholinesterase ligands as diagnostic tools and treatment for diseases of the nervous system
    Treventis 2320891*

  • Combination products
    Novartis 2320892*

  • Combination of a triptan and an NSAID
    Elan Pharma International 2320893*

  • Chemoprevention of head and neck squamous cell carcinomas
    The USA as represented by the Secretary, Department of Health and Human Services 2320894*

  • CDK modulators
    Exelixis 2320895*

  • Vinpocetine and eburnamonine derivatives for promoting bone growth
    Osteogenex 2320896*

  • Compsns and methods of treating amyloid disease
    Treventis 2320897*

  • Smoking cessation kit and method
    Nabi Biopharmaceuticals 2320898*

  • Dihydrotetrabenaxine for treatment of asthma
    Bioavail Laboratories International (Barbados) 2320899*

  • Use of opioids of opioid mimetics for the treatment of resistant cancer patients
    Universität Ulm 2320900*

  • Therapeutic combination comprising a CDKs inhibitor and an antineoplastic agent
    Nerviano Medical Sciences 2320903*

  • Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
    Kalypsys 2320904*

  • Novel adenine derivatives
    SmithKline Beecham 2320905*

  • Heterocyclic amide derivatives as EP4 receptor antagonists
    Beta Pharma Canada 2320906*

  • Therapeutic compounds
    Merck & Co 2320907*

See more

You may also like

Digital

Pharma cybersecurity challenges: a holistic prescription

Read more
The pharmaceutical sector remains a prime target for cyberattacks. As an industry built on innovation, with extensive investments in research and development (R&D), intellectual property (IP) and patient information, it bridges the divide between business and healthcare, becoming a hotspot in the health data threat landscape

Trending Articles

  1. Pfizer wins battle over Viagra trademark Energy drinks brand Viaguara cannot be registered as an EU trademark
  2. Patent applications published 7 July 2010 Selected patent applications from the weekly European Patents Bulletin
  3. Genmab says GSK has settled patent case with Genentech Concerning two US patents for ofatumumbab
  4. Boehringer Ingelheim suffers Spiriva patent blow in India Indian patent office has revoked a patent granted for tiotropium bromide monohydrate under the Spiriva brand, paving the way for Cipla to continue selling its generic version in the Indian market
  5. Phillips-Medisize acquires mini-tablet dispenser patent The US company has acquired exclusive ownership of the patent from a global pharmaceutical company and expects to make the product available by early 2020

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Digital

Pharma cybersecurity challenges: a holistic prescription

The pharmaceutical sector remains a prime target for cyberattacks. As an industry built on innovation, with extensive investments in research and development (R&D), intellectual property (IP) and patient information, it bridges the divide between business and healthcare, becoming a hotspot in the health data threat landscape
Regulatory

Pharmaseal reaches milestone in crowdfunding campaign

The company was first founded in 2016
Patient Experience

Ilya Pharma awarded engineered lactic acid bacterial strain patent

The patent covers the use of engineered lactic acid bacterial strains for all human and animal wounds, not just skin
Pharmaceutical

A card in the competition for COVID-19 drug supply

The patent system has come under pressure both politically and, more recently, as pharma companies scale-up their operations to make large amounts of drugs available to treat COVID-19, reports Paul England, Senior Professional Support Lawyer at Taylor Wessing
Ingredients

Sigrid Therapeutics obtains US patent for silica-based biomaterial SiPore15 for the treatment and prevention of obesity

Mesoporous silica particles (MSP) are a type of ingestible synthetic amorphous silica particles that can be produced with a large surface area and a range of pore sizes
Ingredients

VistaGen and Nuformix agree to develop cocrystalline forms of AV-101

The drug for treatment of multiple CNS conditions will be reformed into a novel patentable form to potentially improve delivery and give more intellectual property protection
Digital

Documentation complexity at crisis point?

Do we focus too much on the paperwork, to the detriment of product and patients? Has documentation become so complex it’s become a dangerous distraction and your biggest risk? by Martin Lush
Subscribe now